Status: Recruiting
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 50+Biological sex: AllType: InterventionalSponsor: Eyconis INC.Updated: Jun 29, 2026Locations: 5
Eligibility criteria
Men or women 50 years and older with neovascular (wet) AMD meeting all study-spe... [+2]
Known hypersensitivity or known allergy that would preclude study drug administr... [+6]